N@N

SOUTH SAN FRANCISO, Calif.--([ BUSINESS WIRE ])--Fluidigm Corporation (NASDAQ:FLDM) today announced the availability of the Access Arraya" Barcode Library for the Ion Torrent Personal Genome Machine (PGM) sequencer. This barcode library allows multiplexing of up to 96 different samples in a single sequencing run.

aThe Access Array Barcode Library for the Ion Torrent PGM enables the growing base of Ion Torrent users to dramatically improve their sample preparation for amplicon sequencing. The library uses a bidirectional amplicon tagging approach to allow reads to be obtained from both ends and across the full length of the amplicon with single-read sequencing. This eliminates the need for paired-end read sequencing,a said Gajus Worthington, Fluidigm President and CEO.

The Fluidigm Access Array System prepares amplicons for resequencing without the need for any additional library preparation and can operate with any next-generation sequencer (NGS) on the market. It prepares these amplicons in just hours, instead of days, and performs the sample preparation for less than $10 per sample. In addition, using the Access Array Barcode Libraries developed for the Illumina, Roche, and Ion Torrent sequencing platforms, researchers can test the same amplicon pools to cross-validate sequencing results across different NGS platforms.

Use of Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements relating to our new products/services and our plans, objectives, expectations and/or strategies relating to such new products/services. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results. Factors that could materially affect future results include, but are not limited to, challenges inherent in developing, manufacturing, and launching new products and services and the other risk factors contained in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q. These forward- looking statements speak only as of the date hereof. Fluidigm Corporation disclaims any obligation to update these forward-looking statements.

About Fluidigm

Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigmas proprietary microfluidic systems consist of instruments and consumables, including chips, assays and other reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets three microfluidic systems, including eight different commercial chips, to leading pharmaceutical and biotechnology companies, academic institutions and Ag-Bio companies.

For more information, please visit [ www.fluidigm.com ].

Fluidigm, the Fluidigm logo, Access Array are trademarks or registered trademarks of Fluidigm Corporation.